ResMed (NYSE:RMD) Director Peter Farrell Sells 8,000 Shares of Stock

ResMed Inc. (NYSE:RMD) Director Peter Farrell sold 8,000 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total value of $1,800,000.00. Following the transaction, the director directly owned 52,773 shares in the company, valued at approximately $11,873,925. The trade was a 13.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Stock Performance

Shares of RMD opened at $223.77 on Friday. ResMed Inc. has a 12 month low of $180.26 and a 12 month high of $293.81. The stock has a fifty day moving average price of $200.06 and a 200-day moving average price of $222.30. The company has a current ratio of 3.01, a quick ratio of 2.33 and a debt-to-equity ratio of 0.06. The firm has a market cap of $32.46 billion, a PE ratio of 21.58, a P/E/G ratio of 1.36 and a beta of 0.76.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.89 by $0.06. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.46 billion. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.55 EPS. Equities research analysts predict that ResMed Inc. will post 11.14 earnings per share for the current fiscal year.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, exceeding the approximately $2.89–$2.90 analyst consensus and rising from $2.55 a year earlier. Revenue reached $1.46 billion, in line with estimates and up 8.6% year over year, supporting the company’s growth narrative. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company also announced a dividend increase alongside strong fourth-quarter and full-year fiscal 2026 results, potentially improving the stock’s appeal to income-oriented investors. ResMed Reports Strong Q4 Results and Dividend Increase
• Positive Sentiment: Management’s earnings call follows a quarter with a 27.44% net margin and 25.35% return on equity, indicating continued profitability and operating strength. ResMed Q4 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst views on ResMed remain mixed, which may be limiting the market’s reaction despite the earnings beat. Earlier previews also highlighted tariff, inflation and hospital-spending risks facing medtech companies. Analysts Have Conflicting Sentiments on ResMed
• Negative Sentiment: Director Peter C. Farrell sold 8,000 shares worth $1.8 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but it may still add modest short-term selling pressure. SEC Insider Trading Filing

Hedge Funds Weigh In On ResMed

A number of institutional investors have recently modified their holdings of RMD. Bank of New York Mellon Corp purchased a new position in shares of ResMed during the 2nd quarter valued at approximately $818,030,000. First Trust Advisors LP grew its position in ResMed by 240.9% during the fourth quarter. First Trust Advisors LP now owns 1,517,592 shares of the medical equipment provider’s stock valued at $365,542,000 after buying an additional 1,072,394 shares during the period. Norges Bank purchased a new position in ResMed in the fourth quarter valued at $249,068,000. Deutsche Bank AG raised its position in shares of ResMed by 126.0% in the fourth quarter. Deutsche Bank AG now owns 1,413,477 shares of the medical equipment provider’s stock worth $340,464,000 after acquiring an additional 787,949 shares during the period. Finally, Amundi boosted its stake in shares of ResMed by 123.9% during the 1st quarter. Amundi now owns 1,062,184 shares of the medical equipment provider’s stock worth $238,439,000 after acquiring an additional 587,872 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RMD. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ResMed in a report on Wednesday, July 1st. JPMorgan Chase & Co. assumed coverage on ResMed in a research note on Wednesday, April 15th. They issued an “overweight” rating for the company. Royal Bank Of Canada cut ResMed from an “outperform” rating to a “sector perform” rating and set a $234.00 price target for the company. in a research report on Thursday, July 16th. Citigroup reissued a “neutral” rating and issued a $235.00 price objective (down from $270.00) on shares of ResMed in a report on Sunday, July 12th. Finally, Mizuho decreased their target price on ResMed from $235.00 to $220.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Seven investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $246.25.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.